Gavin Clark-Gartner
Stock Analyst at Evercore ISI Group
(2.23)
# 2,786
Out of 5,148 analysts
40
Total ratings
50%
Success rate
-3.44%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gavin Clark-Gartner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Outperform | $232 → $228 | $234.26 | -2.67% | 6 | Feb 5, 2026 | |
| DYN Dyne Therapeutics | Maintains: Outperform | $38 → $36 | $16.15 | +122.91% | 1 | Dec 15, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $89 → $94 | $90.09 | +4.34% | 4 | Dec 9, 2025 | |
| VERA Vera Therapeutics | Maintains: Outperform | $75 → $97 | $40.42 | +139.98% | 1 | Dec 8, 2025 | |
| EVMN Evommune | Initiates: Outperform | $40 | $25.61 | +56.19% | 1 | Dec 1, 2025 | |
| FBRX Forte Biosciences | Initiates: Outperform | $65 | $30.65 | +112.07% | 1 | Nov 25, 2025 | |
| ARGX argenx SE | Maintains: Outperform | $775 → $910 | $756.76 | +20.25% | 5 | Oct 31, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Outperform | $20 → $14 | $1.35 | +937.04% | 4 | Sep 22, 2025 | |
| PRQR ProQR Therapeutics | Initiates: Outperform | $5 | $1.58 | +216.46% | 1 | Apr 29, 2025 | |
| CABA Cabaletta Bio | Downgrades: In-Line | $15 → $6 | $3.30 | +81.82% | 2 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $179 → $170 | $16.32 | +941.67% | 9 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $5.76 | +247.22% | 1 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $201 → $206 | $258.81 | -20.40% | 1 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $3.05 | +621.31% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $10 | $3.17 | +215.46% | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $60 | $77.49 | -22.57% | 1 | Oct 5, 2022 |
AbbVie
Feb 5, 2026
Maintains: Outperform
Price Target: $232 → $228
Current: $234.26
Upside: -2.67%
Dyne Therapeutics
Dec 15, 2025
Maintains: Outperform
Price Target: $38 → $36
Current: $16.15
Upside: +122.91%
Mirum Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $89 → $94
Current: $90.09
Upside: +4.34%
Vera Therapeutics
Dec 8, 2025
Maintains: Outperform
Price Target: $75 → $97
Current: $40.42
Upside: +139.98%
Evommune
Dec 1, 2025
Initiates: Outperform
Price Target: $40
Current: $25.61
Upside: +56.19%
Forte Biosciences
Nov 25, 2025
Initiates: Outperform
Price Target: $65
Current: $30.65
Upside: +112.07%
argenx SE
Oct 31, 2025
Maintains: Outperform
Price Target: $775 → $910
Current: $756.76
Upside: +20.25%
Jasper Therapeutics
Sep 22, 2025
Maintains: Outperform
Price Target: $20 → $14
Current: $1.35
Upside: +937.04%
ProQR Therapeutics
Apr 29, 2025
Initiates: Outperform
Price Target: $5
Current: $1.58
Upside: +216.46%
Cabaletta Bio
Dec 20, 2024
Downgrades: In-Line
Price Target: $15 → $6
Current: $3.30
Upside: +81.82%
Nov 7, 2024
Maintains: Outperform
Price Target: $179 → $170
Current: $16.32
Upside: +941.67%
Aug 19, 2024
Initiates: Outperform
Price Target: $20
Current: $5.76
Upside: +247.22%
Aug 12, 2024
Maintains: Outperform
Price Target: $201 → $206
Current: $258.81
Upside: -20.40%
Oct 3, 2023
Initiates: Outperform
Price Target: $22
Current: $3.05
Upside: +621.31%
May 30, 2023
Maintains: Outperform
Price Target: $20 → $10
Current: $3.17
Upside: +215.46%
Oct 5, 2022
Maintains: Outperform
Price Target: $54 → $60
Current: $77.49
Upside: -22.57%